Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lofexidine - Britannia Pharmaceuticals

Next Previous
X
Search
Drug Profile

Lofexidine - Britannia Pharmaceuticals

Alternative Names: BA-168; BritLofex; Lofexidine hydrochloride; LUCEMYRA; MDL-14042; MDL-14042A; RMI-14042A

Latest Information Update: 10 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; National Institute of Drug Abuse; Salix Pharmaceuticals; US WorldMeds
  • Class Antihypertensives; Chlorobenzenes; Drug withdrawal therapies; Imidazolines; Phenyl ethers; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Opioid-related disorders

Highest Development Phases

  • Marketed Opioid-related disorders

Most Recent Events

  • 10 Dec 2024 US WorldMeds plans a phase I trial for Opioid-related disorders (In children, In adolescents) in USA (PO), in 2025 (NCT06711640)
  • 02 Oct 2023 Phase-II clinical trials in Opioid-related disorders (In neonates) in USA (PO) (NCT06047834)
  • 21 Sep 2023 US WorldMeds in collaboration with National Institute of Drug Abuse plans a phase II trial for Opioid withdrawal (In neonates) (PO) (NCT06047834)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top